FDA approves Ocaliva for PBC
Algolia Search

FDA approves Ocaliva for PBC

FDA Approves Ocaliva, New Drug for Primary Biliary Cirrhosis (PBC)

The U.S. Food and Drug Administration (FDA) has approved Intercept Pharmaceuticals’ Ocaliva (obeticholic acid) to treat primary biliary cholangitis, previously known as primary biliary cirrhosis ( PBC), Fierce Biotech reports. The drug is approved for use in combination with ursodeoxycholic acid (UDCA) in adults who have responded inadequately to that drug or as a monotherapy in adults who cannot tolerate UDCA.

FDA approves Ocaliva for PBC - a rare chronic liver disease.pdf